NasdaqGS - Nasdaq Real Time Price USD

Phathom Pharmaceuticals, Inc. (PHAT)

3.9600

+0.0600

+(1.54%)

At close: April 22 at 4:00:01 PM EDT

4.1300

+0.17

+(4.29%)

Pre-Market: 8:37:05 AM EDT

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. A live webcast and additional i

GlobeNewswire 48 minutes ago

PHAT
+1.54%
Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...

Simply Wall St. 6 days ago

PHAT
+1.54%
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therap

GlobeNewswire 7 days ago

PHAT
+1.54%
CDTX
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 15 days ago

RYTM

PHAT
+1.54%
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET. Company management will also participate in one-on-one meetings during the conference,

GlobeNewswire 20 days ago

PHAT
+1.54%
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Steven Basta as President and Chief Executive Officer, the Company’s Board of Directors has approved the grant of inducement awards. The Board of Directors approved the grant to Mr. Basta of a non-qualified stock opt

GlobeNewswire 21 days ago

PHAT
+1.54%
Phathom Pharmaceuticals Announces Leadership Succession

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for

GlobeNewswire 22 days ago

PHAT
+1.54%
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaignVOQUEZNA is a potassium competitive acid blocker (PCAB), the first and only FDA-approved treatment of its kind for both types of GERD1 A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a bio

GlobeNewswire 23 days ago

PHAT
+1.54%
Phathom Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Phathom Pharmaceuticals ( NASDAQ:PHAT ) Full Year 2024 Results Key Financial Results Revenue: US$55.3m (up by US$54.6m...

Simply Wall St. last month

PHAT
+1.54%
Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...

Phathom Pharmaceuticals Inc (PHAT) secures FDA approval for non-erosive GERD, but faces a GAAP net loss and anticipates increased expenses in 2025.

GuruFocus.com last month

PHAT
+1.54%
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 19.39% and 17.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

PHAT
+1.54%
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, approximately a 110% increase since last earnings reportPhase 2 EoE trial for VOQUEZNA nearing initiation, with first patient enrollment planned for Q2 2025Management to host conference call today, March 6, 2025, at 8:30 a.m. ET FLORHAM PARK, N.J

GlobeNewswire last month

PHAT
+1.54%
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update. A live webcast an

GlobeNewswire last month

PHAT
+1.54%
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET. Company management will also participate in one-on-one meetings during the conference

GlobeNewswire 2 months ago

PHAT
+1.54%
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic?

We feel now is a pretty good time to analyse Phathom Pharmaceuticals, Inc.'s ( NASDAQ:PHAT ) business as it appears the...

Simply Wall St. 3 months ago

PHAT
+1.54%
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?

PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. […]

Insider Monkey 4 months ago

PHAT
+1.54%
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listingsPhathom believes applicable law mandates a 10-year NCE exclusivity period (from date of first approval of drug containing vonoprazan) benefitting all vonoprazan-based products, with exclusivity until May 3, 2032 FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on d

GlobeNewswire 4 months ago

PHAT
+1.54%
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround

Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 4 months ago

PHAT
+1.54%
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know

Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 4 months ago

PHAT
+1.54%
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Phathom Pharmaceuticals Inc (PHAT) reports a significant revenue increase and strong market penetration for VOQUEZNA, despite ongoing financial challenges.

GuruFocus.com 5 months ago

PHAT
+1.54%

Performance Overview

Return	PHAT	S&P 500 (^GSPC)
YTD	-51.23%	-10.10%
1-Year	-56.05%	+5.53%
3-Year	-70.88%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals Announces Leadership Succession

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Phathom Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic?

Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Performance Overview